{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-088857","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2026-07-31T00:02:23+00:00","discovered_at":"2026-07-31T10:05:00.275566+00:00","generated_at":"2026-07-31T10:05:21.535685+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Replimune's RP1 gets favorable FDA advisory committee vote 10-3 for advanced melanoma","bullets":["FDA advisory committee voted 10 to 3 that efficacy results from IGNYTE study are evaluable and clinically meaningful.","RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma after anti-PD-1 progression.","FDA target action date for BLA resubmission is August 2, 2026.","CEO Sushil Patel expressed gratitude and looks forward to working with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-088857","json":"https://secwatch.observer/filing/0001104659-26-088857.json","markdown":"https://secwatch.observer/filing/0001104659-26-088857.md","text":"https://secwatch.observer/filing/0001104659-26-088857.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926088857/0001104659-26-088857-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926088857/tm2621708d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-31T10:05:21.535685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}